Analysis of adverse drug reactions to antibacterial agents for systemic use in children

Abstract

The rational use of antibacterial agents (ABAs) for systemic use is crucial to the pediatric population, since every year the abovementioned drugs are most often prescribed to children under two years old, and inappropriate use of ABAs at an early age contributes to an increased risk of comorbidities in children. The study aimed to analyze the frequency of adverse reactions in children to ABAs (by J01 antibacterial drugs for systemic use) in Ukraine during the period of 2018–2023 and highlight those that have the highest rates of adverse reactions.